The blood-brain barrier (BBB) and neuroimmune interface represent interconnected systems whose dysfunction critically contributes to the pathogenesis of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies share common features of tau protein accumulation, but exhibit distinct patterns of BBB disruption and neuroimmune activation that correlate with their unique clinical phenotypes. Understanding the crosstalk between vascular dysfunction and immune responses provides critical insights into disease mechanisms and therapeutic targeting opportunities.
In CBS and PSP, the BBB undergoes progressive dysfunction that enables peripheral immune cell infiltration, compromises clearance of toxic proteins, and establishes a chronic neuroinflammatory milieu.[@van2025] Simultaneously, microglia and astrocytes adopt reactive phenotypes that further degrade vascular integrity, creating a feed-forward loop between neuroinflammation and vascular dysfunction. This page synthesizes current understanding of these interconnected pathways and their therapeutic implications for 4R-tauopathies.
The neurovascular unit (NVU) comprises multiple cell types that collectively maintain brain homeostasis:
The blood-brain barrier (BBB) and neuroimmune interface represent interconnected systems whose dysfunction critically contributes to the pathogenesis of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies share common features of tau protein accumulation, but exhibit distinct patterns of BBB disruption and neuroimmune activation that correlate with their unique clinical phenotypes. Understanding the crosstalk between vascular dysfunction and immune responses provides critical insights into disease mechanisms and therapeutic targeting opportunities.
In CBS and PSP, the BBB undergoes progressive dysfunction that enables peripheral immune cell infiltration, compromises clearance of toxic proteins, and establishes a chronic neuroinflammatory milieu.[@van2025] Simultaneously, microglia and astrocytes adopt reactive phenotypes that further degrade vascular integrity, creating a feed-forward loop between neuroinflammation and vascular dysfunction. This page synthesizes current understanding of these interconnected pathways and their therapeutic implications for 4R-tauopathies.
The neurovascular unit (NVU) comprises multiple cell types that collectively maintain brain homeostasis:
In 4R-tauopathies, the NVU undergoes characteristic changes:
| Component | PSP Changes | CBS Changes | Functional Impact |
|-----------|-------------|-------------|------------------|
| Endothelial cells | Tau accumulation in endothelial cytoplasm | Asymmetric involvement | Reduced tight junction integrity |
| Pericytes | 30-40% coverage reduction | Variable loss | Impaired capillary regulation |
| Astrocyte end-feet | Tufted astrocyte formation | Reactive astrocytosis | Disrupted BBB maintenance |
| Tight junctions | Claudin-5 downregulation | Regional specificity | Increased paracellular leak |
Evidence from dynamic contrast-enhanced MRI (DCE-MRI) studies demonstrates increased BBB permeability in PSP patients, particularly in the basal ganglia and brainstem regions that show the highest tau pathology burden[@van2025]
Pathological tau accumulates in brain endothelial cells in 4R-tauopathies, directly compromising barrier function:
Pericytes are particularly vulnerable in PSP and CBS:
Astrocyte pathology in PSP directly impacts BBB integrity:
Microglial activation in CBS and PSP follows distinct patterns from Alzheimer's disease:
PSP Microglia:
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) plays a crucial role in microglial responses to tau pathology:
| TREM2 Function | PSP/CBS Relevance | Therapeutic Target |
|----------------|-------------------|-------------------|
| Lipid sensing | Tau aggregates have lipid components | TREM2 agonists |
| Phagocytosis | Impaired clearance of tau debris | Enhance activation |
| DAM phenotype | Reduced disease-associated microglia | Metabolic support |
| Cytokine production | Elevated IL-1β, IL-6, TNF-α | NLRP3 inhibitors |
Genetic studies show TREM2 variants associate with PSP risk, though the effect is weaker than in Alzheimer's disease. This suggests TREM2 dysfunction contributes to, but is not the primary driver of, 4R-tauopathy pathogenesis.
The NLRP3 inflammasome is activated in tauopathies, driving production of pro-inflammatory cytokines:
Activation triggers:
A novel axis of crosstalk involves direct communication between pericytes and microglia:
This creates a vicious cycle where pericyte loss leads to microglial activation, which then accelerates pericyte and endothelial damage.
Pro-inflammatory cytokines directly compromise BBB integrity:
| Cytokine | BBB Effect | Source |
|----------|------------|--------|
| TNF-α | Tight junction degradation | Microglia, astrocytes |
| IL-1β | Upregulates adhesion molecules | Activated microglia |
| IL-6 | Increases permeability | Various cell types |
| IFN-γ | Disrupts tight junctions | T-cells (if infiltrating) |
BBB breakdown enables peripheral immune cell entry:
The complement system mediates synaptic elimination and inflammatory responses in 4R-tauopathies:
| Target | Agent | Status | Mechanism |
|--------|-------|--------|-----------|
| C1q | ANX005 | Phase 3 | Antibody inhibition |
| C3 | Pegcetacoplan | Approved (PNH) | C3 inhibitor |
| CR3 | Small molecule antagonists | Preclinical | Block phagocytosis |
Comparative studies reveal disease-specific cytokine profiles:
Focused ultrasound (FUS) with microbubbles temporarily disrupts the BBB for enhanced drug delivery:
Receptor-mediated transcytosis exploits endogenous transport systems:
| Receptor | Ligand | Therapeutic Application | Status |
|----------|--------|------------------------|--------|
| Transferrin receptor | Transferrin | Antibody delivery | Clinical trials |
| Insulin receptor | Insulin | Peptide delivery | Preclinical |
| LDL receptor | Apolipoprotein E | LNP targeting | Research |
| LRP1 | Various | Peptide conjugates | Research |
Given the crosstalk between BBB dysfunction and neuroimmune activation, combination approaches may be most effective:
| Strategy | Target | Rationale |
|----------|--------|-----------|
| FUS + immunotherapy | BBB + tau pathology | Enhanced antibody brain penetration |
| Pericyte stabilization + TREM2 agonist | NVU + microglia | Address both compartments |
| NLRP3 inhibitor + BBB modulator | Neuroinflammation + permeability | Break vicious cycle |
| Complement inhibition + neurotrophins | Synaptic protection + repair | Preserve remaining neurons |
| Biomarker | Source | Interpretation |
|-----------|--------|----------------|
| CSF/serum albumin ratio | CSF, blood | Elevated indicates BBB leak |
| sPDGFR-β | Blood | Pericyte injury marker |
| MMP-9 | CSF | Tight junction degradation |
| Claudin-5 | CSF | Tight junction protein loss |
| Biomarker | Source | Disease Correlation |
|-----------|--------|-------------------|
| YKL-40 | CSF | Astrocyte activation |
| sTREM2 | CSF | Microglial activation |
| IL-1β | CSF | Inflammasome activity |
| GFAP | Blood | Astrocyte reactivity |